# Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

Study · id `cardio:ct-nct05164263` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05164263](<https://clinicaltrials.gov/study/NCT05164263>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05164263

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT05164263. Allocation not applicable; no masking; primary purpose treatment. Start 2021-04-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT05164263, source copy `cardio:ctgov-nct05164263-2026-01-22`, retrieved 2026-10-26)
- Started: 2021-04-01 (actual) (ClinicalTrials.gov record NCT05164263, source copy `cardio:ctgov-nct05164263-2026-01-22`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05164263, source copy `cardio:ctgov-nct05164263-2026-01-22`, retrieved 2026-10-26)
- Completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT05164263, source copy `cardio:ctgov-nct05164263-2026-01-22`, retrieved 2026-10-26)
- Countries: Afghanistan; Kenya; Nigeria; Pakistan; Sri Lanka (ClinicalTrials.gov record NCT05164263, source copy `cardio:ctgov-nct05164263-2026-01-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05164263-2026-01-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
- Acronym: EASE
- Condition: Type II Diabetes Mellitus
- Condition: Efficacy, Self
- Condition: Safety Issues
- Intervention (Drug): Empagliflozin
- Lead sponsor: Getz Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Getz Pharma (`cardio:org-getz-pharma`)

## Provenance

Content hash: 4a6a5e18439e710d1bc40aa353124e2f3702b5cf450b800dfcea9442966e6f18
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
